Groupama Asset Managment Purchases Shares of 250,000 Haemonetics Co. (NYSE:HAE)

Groupama Asset Managment acquired a new stake in Haemonetics Co. (NYSE:HAE) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 250,000 shares of the medical instruments supplier’s stock, valued at approximately $19,520,000. Groupama Asset Managment owned 0.50% of Haemonetics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Whittier Trust Co. acquired a new stake in Haemonetics in the fourth quarter valued at $62,000. Parkside Financial Bank & Trust increased its stake in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. AlphaQuest LLC raised its holdings in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after purchasing an additional 1,826 shares in the last quarter. KBC Group NV lifted its position in shares of Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in shares of Haemonetics in the 3rd quarter valued at $204,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Price Performance

Shares of NYSE HAE opened at $63.65 on Tuesday. The stock has a fifty day moving average price of $65.85 and a 200 day moving average price of $74.63. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market cap of $3.20 billion, a PE ratio of 25.06, a P/E/G ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on HAE shares. Needham & Company LLC reduced their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, Raymond James restated a “strong-buy” rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.